A PHASE 1B, OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION STUDY OF THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF CERGUTUZUMAB AMUNALEUKIN, AN IMMUNOCYTOKINE, WHICH CONSISTS OF A VARIANT OF INTERLEUKIN-2 (IL-2v) TARGETING CARCINOEMBRYONIC ANTIGEN (CEA), AND ATEZOLIZUMAB, AN ANTIBODY TARGETING PROGRAMMED DEATH-LIGAND 1 (PD-L1) ADMINISTERED IN COMBINATION INTRAVENOUSLY, IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC SOLID TUMORS
Study of Drug in Non-Small Cell Lung Cancer
Sponsor: F. Hoffmann- La Roche Ltd.
Enrolling: Male and Female Patients
IRB Number: AAAR5186
U.S. Govt. ID: NCT02350673
Contact: Naiyer Rizvi MD: 646-317-3141 / nar2144@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the safety of the study drugs and how well your body tolerates it. The study will also test how well the study drugs work to slow down the growth of you tumor or stop your cancer. The study drugs are Cergutuzumab Amunaleukin and Atezolizumab. Atezolizumab is FDA approved for the treatment of patients with metastatic non-small cell lung cancer. Cergutuzumab Amunaleukin is an investigational new drug that has not been approved for treatment.
This study is closed
Do You Qualify?
Are you 18 years or older? Yes No
Do you have a confirmed solid tumor? Yes No
Do you have a life expectancy of 12 weeks or more? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Naiyer Rizvi MD
nar2144@cumc.columbia.edu
646-317-3141